Indo US Bio-Tech

What does Indo US Bio-Tech do?

Indo US Bio-Tech Ltd is a Micro Cap company in the Other Agricultural Products industry, reporting net sales of 33 Cr and a net profit of 4 Cr for March 2025. The company, originally founded in 2004, has undergone several name changes and has a market cap of Rs 327 Cr.

Overview:<BR>Indo US Bio-Tech Ltd operates in the Other Agricultural Products industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as Pollucid Bio-Tech Private Limited in 2004. It underwent several name changes, becoming Pellucid Bio-Tech Private Limited in 2005 and later Indo US Bio-Tech Private Limited in 2007. The latest quarterly results report net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 33 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 4 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 327 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 20.00<BR>- Industry P/E: 54<BR>- Dividend Yield: 0.13%<BR>- Debt Equity: 0.19<BR>- Return on Equity: 20.71%<BR>- Price to Book: 4.08<BR><BR>Contact Details:<BR>Address: 309 Shanti Mall, Satadhar Char Rasta Sola Road Ahmedabad Gujarat : 380061<BR>Tel: 91-79-27491807<BR>Email: compliance@indousagriseeds.com<BR>Website: http://www.indousagriseeds.com

What is the bonus history of the Indo US Bio-Tech?

Indo US Bio-Tech has a history of issuing bonus shares, with the most recent being a 1:1 bonus on August 29, 2023, following a 1:5 bonus on November 29, 2021, and a 1:4 bonus on April 23, 2019. This reflects the company's commitment to rewarding its shareholders.

Indo US Bio-Tech has a notable bonus history. The most recent bonus issue was a 1:1 bonus announced with an ex-date of August 29, 2023. Prior to that, the company issued a 1:5 bonus on November 29, 2021, and a 1:4 bonus on April 23, 2019. This shows a consistent approach to rewarding shareholders through bonus shares over the years.

Has Indo US Bio-Tech declared dividend?

Indo US Bio-Tech Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of December 3, 2024. Recent total returns have shown significant volatility, with a total return of -42.67% over the last 6 months, but positive long-term returns over 2, 3, 4, and 5 years.

Indo US Bio-Tech Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 03 Dec 2024<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -42.67%, with a dividend return of 0%, resulting in a total return of -42.67%.<BR><BR>Over the past year, the price return was -22.47%, the dividend return was 0.09%, leading to a total return of -22.38%.<BR><BR>In the 2-year period, the price return was 42.53%, with a dividend return of 0.19%, resulting in a total return of 42.72%.<BR><BR>For the 3-year period, the price return was 472.63%, the dividend return was 0.71%, culminating in a total return of 473.34%.<BR><BR>In the last 4 years, the price return was 962.85%, with a dividend return of 2.39%, leading to a total return of 965.24%.<BR><BR>Over the past 5 years, the price return was 686.51%, with a dividend return of 2.09%, resulting in a total return of 688.6%.<BR><BR>Overall, while Indo US Bio-Tech has declared a dividend, the recent total returns show significant volatility, particularly in the shorter periods, indicating a challenging performance in the near term despite positive long-term returns.

Who are the peers of the Indo US Bio-Tech?

Indo US Bio-Tech's peers include L T Foods, KRBL, Kaveri Seed Co., and others, with varying management risks and growth rates. L T Foods has the highest 1-year return at 111.90%, while Indo US Bio-Tech's return is -25.46%.

Peers: The peers of Indo US Bio-Tech are L T Foods, KRBL, Kaveri Seed Co., Guj. Ambuja Exp, GRM Overseas, Aelea, Tierra Agrotech, Prime Fresh, Halder Venture, and MANGALAM SEEDS.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kaveri Seed Co., while Good management risk is found at Indo US Bio-Tech and L T Foods. Average management risk is present at KRBL, Guj. Ambuja Exp, GRM Overseas, Aelea, Prime Fresh, and Halder Venture, and the rest. Below Average management risk is noted at Tierra Agrotech. In terms of growth, Excellent growth is seen at Aelea, Good growth is found at Indo US Bio-Tech, L T Foods, and Prime Fresh, while Below Average growth is observed at KRBL, Kaveri Seed Co., Guj. Ambuja Exp, and the rest. Finally, Excellent capital structure is noted at KRBL, Kaveri Seed Co., and Guj. Ambuja Exp, while Good capital structure is present at Indo US Bio-Tech, L T Foods, and Prime Fresh, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is L T Foods at 111.90%, while the peer with the lowest is Tierra Agrotech at -30.50%. Indo US Bio-Tech's 1-year return is -25.46%, which is significantly lower than L T Foods and higher than Tierra Agrotech. Additionally, several peers, including Aelea, Tierra Agrotech, Halder Venture, and MANGALAM SEEDS, have negative six-month returns.

What is the technical trend for Indo US Bio-Tech?

As of May 26, 2025, the market trend is mildly bearish, with daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mixed indicators like the MACD and KST showing mild bullishness in the short term.

As of 26 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a bearish signal. The MACD presents a mixed picture with a mildly bullish signal on the weekly but mildly bearish on the monthly. The KST aligns with this by being mildly bullish weekly and mildly bearish monthly. The OBV is consistently mildly bearish across both time frames. Overall, while there are some mildly bullish indicators, the prevailing sentiment remains bearish, particularly in the short term.

Who are in the management team of Indo US Bio-Tech?

As of March 2022, the management team of Indo US Bio-Tech includes Jagdish Ajudia (Chairman & Managing Director), Maltiben Ajudia (Whole-time Director), Priyanka Ajudia (Executive Director), Ritaben Nileshbhai Kikani (Non-Executive & Independent Director), and Dimpy Joshi (Company Secretary). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Indo US Bio-Tech includes the following individuals:<BR><BR>1. Jagdish Ajudia - Chairman & Managing Director<BR>2. Maltiben Ajudia - Whole-time Director<BR>3. Priyanka Ajudia - Executive Director<BR>4. Ritaben Nileshbhai Kikani - Non-Executive & Independent Director<BR>5. Dimpy Joshi - Company Secretary<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Who are the top shareholders of the Indo US Bio-Tech?

The top shareholder of Indo US Bio-Tech is Jagdishkumar Devjibhai Ajudiya, holding 48.82%. Other notable shareholders include Improwised Technologies Private at 1.99% and individual investors with a collective 24.34%.

The top shareholders of Indo US Bio-Tech include the promoters, with Jagdishkumar Devjibhai Ajudiya holding the largest share at 48.82%. There are no pledged promoter holdings, and the company does not have any mutual fund schemes invested in it. Additionally, there is one Foreign Institutional Investor (FII) with a very minimal holding of 0.0%. The highest public shareholder is Improwised Technologies Private, which holds 1.99%. Individual investors collectively hold 24.34% of the shares.

How big is Indo US Bio-Tech?

As of 24th July, Indo US Bio-Tech Ltd has a market capitalization of 346.00 Cr, with recent net sales of 103.83 Cr and a net profit of 16.26 Cr. Shareholder's funds are 38.51 Cr, and total assets amount to 55.20 Cr as of March 2022.

As of 24th July, Indo US Bio-Tech Ltd has a market capitalization of 346.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 103.83 Cr and a Net Profit of 16.26 Cr.<BR><BR>The latest annual period for the balance sheet is March 2022, with Shareholder's Funds amounting to 38.51 Cr and Total Assets of 55.20 Cr.

Are Indo US Bio-Tech latest results good or bad?

Indo US Bio-Tech's latest results show strong year-on-year growth, with a 127.10% increase in Profit After Tax and a 58.43% rise in net sales. However, recent quarterly performance indicates a 7.82% decline in net sales, leading to a cautious outlook, as reflected by MarketsMOJO's 'Sell' recommendation.

Indo US Bio-Tech's latest financial results present a mixed picture. On one hand, the company has demonstrated significant growth in profitability, with a Profit After Tax (PAT) of Rs 8.38 crore for the last six months, reflecting a remarkable year-on-year increase of 127.10%. Additionally, net sales reached Rs 64.15 crore, marking a solid growth of 58.43% compared to the previous year.<BR><BR>However, there are some concerns to note. The quarterly performance for the period ending June 2025 shows a decline in net sales by 7.82% compared to the previous quarter, which contrasts sharply with the strong growth of 41.68% seen in March 2025. While the standalone net profit did increase by 27.72% quarter-on-quarter, the overall trend indicates some volatility.<BR><BR>Despite these positive growth figures, MarketsMOJO has issued a 'Sell' call on the stock, suggesting that there may be underlying concerns that investors should consider. Overall, while there are positive indicators in terms of year-on-year growth, the recent quarterly performance raises some caution about the company's short-term trajectory.

How has been the historical performance of Indo US Bio-Tech?

Indo US Bio-Tech has shown steady growth over the past three years, with net sales increasing from 39.76 crore in March 2020 to 50.06 crore in March 2022, and profit after tax rising from 2.53 crore to 5.06 crore. Despite rising raw material costs, the company improved its operational efficiency and cash flow during this period.

Answer:<BR>The historical performance of Indo US Bio-Tech shows a steady growth in net sales and profit over the past three years.<BR><BR>Breakdown:<BR>Indo US Bio-Tech's net sales increased from 39.76 crore in March 2020 to 50.06 crore in March 2022, reflecting a positive trend in revenue generation. The total operating income followed the same trajectory, rising from 39.76 crore in March 2020 to 50.06 crore in March 2022. However, raw material costs surged significantly from 3.59 crore in March 2020 to 45.20 crore in March 2022, indicating increased operational expenses. Despite this, the operating profit (PBDIT) improved from 3.99 crore in March 2020 to 6.95 crore in March 2022, showcasing better operational efficiency. Profit before tax also rose from 2.86 crore in March 2020 to 5.31 crore in March 2022, while profit after tax increased from 2.53 crore to 5.06 crore in the same period. The company's total assets grew from 34.70 crore in March 2020 to 55.20 crore in March 2022, alongside a rise in total liabilities from 34.70 crore to 55.20 crore. Cash flow from operating activities showed a positive trend, moving from 0.00 crore in March 2021 to 2.00 crore in March 2022, indicating improved cash generation capabilities. Overall, Indo US Bio-Tech has demonstrated consistent growth in sales, profits, and asset accumulation over the past three years.

Is Indo US Bio-Tech overvalued or undervalued?

As of December 4, 2025, Indo US Bio-Tech is considered very attractive and undervalued, with a PE ratio of 15.32, strong growth potential indicated by a PEG ratio of 0.35, and solid financial performance metrics, despite a year-to-date stock performance lagging behind the Sensex.

As of 4 December 2025, the valuation grade for Indo US Bio-Tech has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 15.32, an EV to EBITDA of 14.47, and a PEG ratio of 0.35, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Indo US Bio-Tech stands out with a significantly lower PE ratio than Jain Irrigation at 52.39 and Krishival Foods at 77.88, both of which are considered very expensive. Additionally, the company’s ROE of 19.48% and ROCE of 16.37% further reinforce its strong financial performance. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -59.05% compared to the Sensex's 9.12%, the underlying fundamentals suggest that Indo US Bio-Tech is positioned for recovery and growth.

When is the next results date for Indo US Bio-Tech Ltd?

The next results date for Indo US Bio-Tech Ltd is January 21, 2026.

The next results date for Indo US Bio-Tech Ltd is scheduled for January 21, 2026.

Which are the latest news on Indo US Bio-Tech?

Should I buy, sell or hold Indo US Bio-Tech Ltd?

Why is Indo US Bio-Tech Ltd falling/rising?

As of 19-Jan, Indo US Bio-Tech Ltd's stock price is at Rs. 110.15, reflecting a 3.8% decline and a new 52-week low. Despite increased investor participation, the stock underperformed its sector and is trading below key moving averages, indicating a continued downward trend.

As of 19-Jan, Indo US Bio-Tech Ltd's stock price is falling, currently at Rs. 110.15, which reflects a decrease of Rs. 4.35 or 3.8%. This decline is evident in the stock's performance over various time frames, with a 1-week drop of 3.80% and a 1-month decrease of 10.59%. Additionally, the stock has reached a new 52-week low today, indicating a significant downturn in its value.<BR><BR>Today's trading session has shown high volatility, with the stock experiencing an intraday low of Rs. 110.15 and a high of Rs. 119.9. Despite opening with a gain of 4.72%, the stock ultimately underperformed its sector by 2.16%. Furthermore, it is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals weakness in price momentum.<BR><BR>While there has been a rise in investor participation, as indicated by a 32.18% increase in delivery volume compared to the 5-day average, this has not translated into a positive price movement. Overall, the combination of reaching a new low, underperformance against the sector, and trading below key moving averages contributes to the stock's current downward trend.